Rheumatology Department, Unidade Local de Saúde do Alto Minho, Largo Conde Bertiandos, 4990-041, Ponte de Lima, Portugal.
Rheumatology Department, Hospital de Braga, Braga, Portugal.
Clin Rheumatol. 2021 Aug;40(8):3351-3355. doi: 10.1007/s10067-021-05612-y. Epub 2021 Jan 30.
Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and inflammatory bowel disease (IBD) is rare (Sy et al. in Semin Arthritis Rheum 45:475-482, 2016). Nevertheless, we present a case of an AAV in a 53-year-old female with enteropathic spondylarthritis previously treated with tumor necrosis factor α inhibitors (TNFi). Management of vasculitis in a patient with IBD may be problematic due to the difficulty in distinguishing if the vasculitis is an extraintestinal manifestation of the IBD or a new coexistent entity. Moreover, in our report, the previous treatment with TNFi is a possible confounding factor due to the paradoxical effects induced by TNFi, including vasculitis (Ramos-Casals et al. in Curr Rheumatol Rep 10:442-448, 2008). The reported case alerts to the complexity in the management of patients with enteropathic spondylarthritis and vasculitis, as well as discusses the diversity of differential diagnosis in this particular clinical scenario.
抗中性粒细胞胞质抗体(ANCA)相关性血管炎(AAV)与炎症性肠病(IBD)共存的情况较为罕见(Sy 等人在 Semin Arthritis Rheum 45:475-482, 2016 年)。然而,我们报告了一例 53 岁女性的 AAV 病例,该患者曾患有肠病性脊柱关节炎,并接受过肿瘤坏死因子-α抑制剂(TNFi)治疗。由于难以区分血管炎是 IBD 的肠外表现还是新的共存实体,因此 IBD 患者的血管炎管理可能存在问题。此外,在我们的报告中,先前接受 TNFi 治疗可能是一个混杂因素,因为 TNFi 可引起血管炎等矛盾作用(Ramos-Casals 等人在 Curr Rheumatol Rep 10:442-448, 2008 年)。该病例报告提醒我们在管理肠病性脊柱关节炎和血管炎患者时存在复杂性,同时还讨论了在这种特殊临床情况下进行鉴别诊断的多样性。